Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34189 | 0.97 | GABRA1 (0.33) | BCHEACHEGABRA1GABRB2RIPK1 | |
| SCHEMBL29381329 | 0.97 | GABRA1 (0.33) | BCHEACHEGABRA1GABRB2RIPK1 | |
| SCHEMBL4449614 | 0.93 | RIPK1 (0.34) | BCHEACHEGABRA1GABRB2RIPK1 | |
| SCHEMBL30872867 | 0.89 | PNMT (0.32) | PNMTIDO1ALDH1A1MEN1KMT2A | |
| SCHEMBL17750351 | 0.89 | GABRA1 (0.43) | GABRA1GABRB2ALDH1A1MEN1KMT2A | |
| SCHEMBL20732795 | 0.85 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL3680536 | 0.84 | TAAR1 (0.43) | ACHEALDH1A1MEN1KMT2ATAAR1 | |
| SCHEMBL1948544 | 0.83 | RIPK1 (0.32) | RIPK1SLC6A2 | |
| SCHEMBL1423269 | 0.83 | CYP3A4 (0.31) | RIPK1 | |
| SCHEMBL5598297 | 0.82 | TAAR1 (0.42) | RIPK1IDO1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554039-B1 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINO)METALLOCENE LIGAND | LUCITE INT UK LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-7485739-B2 | Catalyst system | LUCITE INTERNATIONAL UK LTD. (GB) | 2009-02-03 | — | — | US | disclosed |
| US-20060252935-A1 | Catalyst system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| EP-1554039-A2 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINOALKYL)FERROCENE LIGAND | Lucite International UK Limited (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004024322-A2 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINOALKYL) FERROCENE LIGAND | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252935-A1 | Catalyst system | ELOB, SOD1, ESR1 | BCHE 952/4885ACHE 991/4885GABRA1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.